PART 71—[Amended]

1. The authority citation for part 71 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, 1959–1963 Comp., p. 389; 14 CFR 11.69.

§ 71.1 [Amended]

2. The incorporation by reference in 14 CFR 71.1 of the Federal Aviation Administration Order 7400.9D, Airspace Designation and Reporting Points, dated September 4, 1996, and effective September 16, 1996, is amended as follows:

Paragraph 6005 Class E airspace areas extending upward from 700 feet or more above the surface of the earth.

* * * * *

AGL SD E5 Spearfish, SD [Revised]

Black Hills-Clyde Ice Field, SD
(lat. 44°28′49″N, long. 103°46′37″W)

That airspace extending upward from 700 feet above the surface within a 7-mile radius of the Black Hills-Clyde Ice Field Airport and within 2.1 miles each side of the 305° bearing from the airport extending from the 7-mile radius to 8.3 miles northwest of the airport; and that airspace extending upward from 1,200 feet above the surface within an area bounded by a line beginning at lat. 44°29′22″N, long. 103°56′48″W; to lat. 44°13′37″N, long. 104°14′00″W; to lat. 44°18′41″N, long. 104°23′24″W; to lat. 44°44′11″N, long. 103°57′49″W; to lat. 44°50′13″N, long. 103°28′11″W; to lat. 44°47′27″N, long. 102°57′40″W; to lat. 44°39′31″N, long. 102°56′34″W; to lat. 44°38′27″N, long. 103°12′26″W; to lat. 44°25′29″N, long. 103°38′30″W; then clockwise via the 7-mile radius of the airport to the point of beginning.

* * * * *

Issued in Des Plaines, Illinois on February 5, 1997.

Maureen Woods,

Manager, Air Traffic Division.

[FR Doc. 97–4073 Filed 2–18–97; 8:45 am]

BILLING CODE 4910–13–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Ch. I

[Docket No. 96N–0364]

RIN 0910–AA20

Regulation of Medical Foods; Extension of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Advance notice of proposed rulemaking; extension of comment period.

SUMMARY: The Food and Drug Administration (FDA) is extending to April 28, 1997, the comment period for the advance notice of proposed rulemaking for the regulation of medical foods that published in the Federal Register of November 29, 1996. This action is being taken in response to several requests from interested persons for an extension of the comment period on this document.

DATES: Written comments by April 28, 1997.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Robert J. Moore, Center for Food Safety and Applied Nutrition (HFS–456), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–205–4605.

SUPPLEMENTARY INFORMATION: In the Federal Register of November 29, 1996 (61 FR 60661), FDA published an advance notice of proposed rulemaking for the regulation of medical foods. Interested persons were given until February 27, 1997, to comment on the advance notice of proposed rulemaking.

FDA has received requests for an extension of the comment period from: Manufacturers, a trade organization representing manufacturers of medical foods, and a professional society representing health care providers and research scientists. The interested parties stated in their requests for an extension of the comment period that such an extension would help ensure that the agency receives comprehensive and carefully researched information from experts to consider in response to the notice. After careful consideration of the requests submitted to the agency, FDA has decided to grant an extension of the comment period until April 28, 1997.

Interested persons may, on or before April 28, 1997, submit to the Dockets Management Branch (address above) written comments regarding this advanced notice of proposed rulemaking. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This document is issued under sections 4, 5, and 6 of the Fair Packaging and Labeling Act (15 U.S.C. 1453, 1454, 1455); sections 201, 301, 402, 403, 404, 405, 409, 411, 412, 501, 502, 503, 505, and 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321, 331, 342, 343, 344, 345, 348, 350, 350a, 351, 352, 353, 355, 371); and 21 U.S.C. 360ee(b)(3) (section 5(b)(3) of the Orphan Drug Amendments of 1988, as amended by Pub. L. 100–290).

Dated: February 12, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97–4021 Filed 2–18–97; 8:45 am]

BILLING CODE 4160–01–F

21 CFR Part 808

[Docket No. 96N–0249]

RIN 0910–AB03

Exemption From Preemption of State and Local Cigarette and Smokeless Tobacco Requirements; Applications for Exemption Submitted by Various State Governments

AGENCY: Food and Drug Administration, HHS.

ACTION: Proposed rule.

SUMMARY: The Federal Food, Drug, and Cosmetic Act (the act) preempts State and local device requirements that are different from, or in addition to, Federal requirements under the act. The act also provides that the Food and Drug Administration (FDA) may, by regulation, exempt State and local device requirements from preemption. FDA is responding to applications for exemption submitted by the States of Alabama, Alaska, Utah, and Washington. FDA is proposing to grant exemptions from Federal preemption for certain cigarette and smokeless tobacco requirements in the States of Alabama, Alaska, and Utah. The requirements in the State of Washington are not preempted, and therefore no exemption needs to be granted. Elsewhere in this issue of the Federal Register, FDA is announcing an opportunity for interested persons to request a public hearing on the proposed regulation.

DATES: Written comments by March 21, 1997. FDA proposes that any final rule that may be issued based on this proposal become effective 30 days after the date of its publication in the Federal Register.

ADDRESSES: Written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Anne M. Kirchner, Office of Policy (HF–23), Food and Drug Administration,